Various recent efforts have shown that inhibition of glutaminolysis offers synergistic effects when administered alongside anti-NOTCH1, β-lapachone, or BCL-2 inhibition for the treatment of T cell acute lymphoblastic leukaemia (T-ALL), pancreatic cancer, or acute myeloid leukemia (AML), respectively [36–38]. The gene discussed is BCL2; the disease is pancreatic neoplasm.